The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Amino Acid Substitutions in the Cytochrome P-450 Lanosterol 14α-Demethylase (CYP51A1) from Azole-Resistant Candida albicans Clinical Isolates Contribute to Resistance to Azole Antifungal Agents
Open accessAbstract
The cytochrome P-450 lanosterol 14α-demethylase (CYP51A1) of yeasts is involved in an important step in the biosynthesis of ergosterol. Since CYP51A1 is the target of azole antifungal agents, this enzyme is potentially prone to alterations leading to resistance to these agents. Among them, a decrease in the affinity of CYP51A1 for these agents is possible. We showed in a group of Candida albicans isolates from AIDS patients that multidrug efflux transporters were playing an important role in the resistance of C. albicans to azole antifungal agents, but without excluding the involvement of other factors (D. Sanglard, K. Kuchler, F. Ischer, J.-L. Pagani, M. Monod, and J. Bille, Antimicrob. Agents Chemother. 39:2378–2386, 1995). We therefore analyzed in closer detail changes in the affinity of CYP51A1 for azole antifungal agents. A strategy consisting of functional expression in Saccharomyces cerevisiae of the C. albicans CYP51A1 genes of sequential clinical isolates from patients was designed. This selection, which was coupled with a test of susceptibility to the azole derivatives fluconazole, ketoconazole, and itraconazole, enabled the detection of mutations in different cloned CYP51A1 genes, whose products are potentially affected in their affinity for azole derivatives. This selection enabled the detection of five different mutations in the cloned CYP51A1 genes which correlated with the occurrence of azole resistance in clinical C. albicans isolates. These mutations were as follows: replacement of the glycine at position 129 with alanine (G129A), Y132H, S405F, G464S, and R467K. While the S405F mutation was found as a single amino acid substitution in a CYP51A1 gene from an azole-resistant yeast, other mutations were found simultaneously in individual CYP51A1 genes, i.e., R467K with G464S, S405F with Y132H, G129A with G464S, and R467K with G464S and Y132H. Site-directed mutagenesis of a wild-type CYP51A1 gene was performed to estimate the effect of each of these mutations on resistance to azole derivatives. Each single mutation, with the exception of G129A, had a measurable effect on the affinity of the target enzyme for specific azole derivatives. We speculate that these specific mutations could combine with the effect of multidrug efflux transporters in the clinical isolates and contribute to different patterns and stepwise increases in resistance to azole derivatives.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · Pediatrics · doi:10.1542/peds.65.1.187 · Cited by 14,751
Improved method for high efficiency transformation of intact yeast cells
Gietz, D., Jean, A. S., Woods, R. A., & Schiestl, R. H. (1992) · Nucleic Acids Research · doi:10.1093/nar/20.6.1425 · Cited by 3,261
P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature
Nelson, D. R., Koymans, L., Kamataki, T., Stegeman, J. J., Feyereisen, R., Waxman, D. J., Waterman, M. R., Gotoh, O., Coon, M. J., Estabrook, R. W., et al. (1996) · Pharmacogenetics · doi:10.1097/00008571-199602000-00002 · Cited by 2,945
Self-citationResistance of Candida species to fluconazole
Rex, J. H., Rinaldi, M. G., & Pfaller, M. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.1.1 · Cited by 877
Sanglard, D., Kuchler, K., Ischer, F., Pagani, J. L., Monod, M., & Bille, J. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.11.2378 · Cited by 815
Self-citationWhite, T. C. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1482 · Cited by 612
Sanglard, D., Ischer, F., Monod, M., & Bille, J. (1997) · Microbiology · doi:10.1099/00221287-143-2-405 · Cited by 587
Self-citationSanglard, D., Ischer, F., Monod, M., & Bille, J. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.10.2300 · Cited by 402
Self-citationKelly, S. L., Lamb, D. C., Corran, A. J., Baldwin, B. C., & Kelly, D. E. (1995) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1995.1272 · Cited by 296
White, T. C. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1488 · Cited by 292
Redding, S., Smith, J., Farinacci, G., Rinaldi, M., Fothergill, A., Rhine-Chalberg, J., & Pfaller, M. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/18.2.240 · Cited by 269
Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance
Albertson, G. D., Niimi, M., Cannon, R. D., & Jenkinson, H. F. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.12.2835 · Cited by 260
Molecular mechanisms of drug resistance in fungi
Vanden Bossche, H., Marichal, P., & Odds, F. C. (1994) · Trends in Microbiology · doi:10.1016/0966-842x(94)90618-1 · Cited by 254
Bissinger, P. H., & Kuchler, K. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)41760-1 · Cited by 231
Nolte, F. S., Parkinson, T., Falconer, D. J., Dix, S., Williams, J., Gilmore, C., Geller, R., & Wingard, J. R. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.1.196 · Cited by 219
Characterization of an azole-resistant Candida glabrata isolate
vanden Bossche, H., Marichal, P., Odds, F. C., Le Jeune, L., & Coene, M. C. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.12.2602 · Cited by 203
Lamb, D. C., Kelly, D. E., Schunck, W.-H., Shyadehi, A. Z., Akhtar, M., Lowe, D. J., Baldwin, B. C., & Kelly, S. L. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.9.5682 · Cited by 193
In vitro and in vivo evaluation of antifungal agents
Espinel-Ingroff, A., & Shadomy, S. (1989) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01963469 · Cited by 179
Primary Structure of the P450 Lanosterol Demethylase Gene from Saccharomyces cerevisiae
KALB, V. F., WOODS, C. W., TURI, T. G., DEY, C. R., SUTTER, T. R., & LOPER, J. C. (1987) · DNA · doi:10.1089/dna.1987.6.529 · Cited by 176
Molecular mechanisms of azole resistance in fungi
Joseph-Horne, T., & Hollomon, D. W. (2006) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.1997.tb10321.x · Cited by 176
Molecular analysis of cyp51 from fluconazole-resistant Candida albicans strains
Löffler, J., Kelly, S. L., Hebart, H. F., Schumacher, U., Lass‐Flörl, C., & Einsele, H. (1997) · FEMS Microbiology Letters · doi:10.1111/j.1574-6968.1997.tb12580.x · Cited by 159
Substituted imidazoles as inhibitors of microsomal oxidation and insecticide synergists
Wilkinson, C. F., Hetnarski, K., & Hicks, L. (1974) · Pesticide Biochemistry and Physiology · doi:10.1016/0048-3575(74)90113-8 · Cited by 158
P450 inhibitors of use in medical treatment: Focus on mechanisms of action
BOSSCHE, H. V., Koymans, L. M. H., & Moereels, H. (1995) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(95)00011-5 · Cited by 153
Self-citationImidazole derivatives—A new class of microsomal enzyme inhibitors
Wilkinson, C. F., Hetnarski, K., & Yellin, T. O. (1972) · Biochemical Pharmacology · doi:10.1016/0006-2952(72)90147-5 · Cited by 130
Mechanisms and clinical impact of antifungal drug resistance
BOSSCHE, H. V., Warnock, D. W., Dupont, B., Kerridge, D., Gupta, S. S., Improvisi, L., Marichal, P., Odds, F. C., Provost, F., & Ronin, O. (1994) · Medical Mycology · doi:10.1080/02681219480000821 · Cited by 129
Biochemical Approaches to Selective Antifungal Activity. Focus on Azole Antifungals
BOSSCHE, H. V., Marichal, P., Gorrens, J., Coene, M. C., Willemsens, G., Bellens, D., Roels, I., Moereels, H., & Janssen, P. A. J. (1989) · Mycoses · doi:10.1111/j.1439-0507.1989.tb02293.x · Cited by 123
Bard, M., Lees, N. D., Turi, T. G., Craft, D., Cofrin, L., Barbuch, R. J., Koegel, C., & Loper, J. C. (1993) · Lipids · doi:10.1007/bf02537115 · Cited by 121
Experimental manipulation of gene expression
Inouye, M. (1983) · Academic Press eBooks · Cited by 120
Molecular analysis of cyp51 from fluconazole-resistant Candida albicans strains
Löffler, J. (1997) · FEMS Microbiology Letters · doi:10.1016/s0378-1097(97)00172-9 · Cited by 119
BOSSCHE, H. V., Marichal, P., Gorrens, J., Bellens, D., Moereels, H., & Janssen, P. A. J. (1990) · Biochemical Society Transactions · doi:10.1042/bst0180056 · Cited by 114
Nucleotide sequence of cytochrome P450 LIAI (lanosterol 14α-demethylase) fromCandida albicans
LAI, M. H., & Kirsch, D. R. (1989) · Nucleic Acids Research · doi:10.1093/nar/17.2.804 · Cited by 106
Troillet, N., Durussel, C., Billé, J., Glauser, M. P., & Chave, J. P. (1993) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01992164 · Cited by 96
Boerlin, P., Boerlin-Petzold, F., Goudet, J., Durussel, C., Pagani, J., Chave, J. P., & Billé, J. (1996) · Journal of Clinical Microbiology · doi:10.1128/jcm.34.5.1235-1248.1996 · Cited by 77
Seghezzi, W., MEILI, C., RUFFINER, R., KUENZI, R., Sanglard, D., & Fiechter, A. (1992) · DNA and Cell Biology · doi:10.1089/dna.1992.11.767 · Cited by 64
Self-citationResistant P45051A1 activity in azole antifungal tolerant Cryptococcus neoformans from AIDS patients
Lamb, D. C., Corran, A. J., Baldwin, B. C., Kwon‐Chung, J., & Kelly, S. L. (1995) · FEBS Letters · doi:10.1016/0014-5793(95)00684-2 · Cited by 64
Modeling cytochrome P450 14α demethylase (Candida albicans) from P450cam
Boscott, P. E., & Grant, G. H. (1994) · Journal of Molecular Graphics · doi:10.1016/0263-7855(94)80086-3 · Cited by 63
Altered P450 activity associated with direct selection for fungal azole resistance
Joseph‐Horne, T., Hollomon, D. W., Loeffler, R. S. T., & Kelly, S. L. (1995) · FEBS Letters · doi:10.1016/0014-5793(95)01102-k · Cited by 59
Isolation of the gene for cytochrome P450 L1A1 (lanosterol 14α-demethylase) from Candida albicans
Kirsch, D. R., LAI, M. H., & O''SULLIVAN, J. (1988) · Gene · doi:10.1016/0378-1119(88)90025-x · Cited by 58
Resistance of clinically important yeasts to antifungal agents
Odds, F. C. (1996) · International Journal of Antimicrobial Agents · doi:10.1016/0924-8579(95)00048-8 · Cited by 54
Oropharyngeal candidiasis resistant to single-dose therapy with fluconazole in HIV-infected patients
Vuffray, A., Durussel, C., Boerlin, P., Boerlin-Petzold, F., Bille, I., Glauser, M. P., & Chave, J. P. (1994) · AIDS · doi:10.1097/00002030-199405000-00023 · Cited by 48
Isolation and analysis of ketoconazole resistant mutants ofSaccharomyces cerevisiae
Watson, P. F., Rose, M. E., & Kelly, S. L. (1988) · Medical Mycology · doi:10.1080/02681218880000231 · Cited by 43
Structure of Cytochrome P450: Heme-Binding Site and Heme Reactivity
de Montellano, P. R. O., & Graham-Lorence, S. E. (1993) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-77763-9_11 · Cited by 9
Cited by
Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance
White, T. C., Marr, K. A., & Bowden, R. A. (1998) · Clinical Microbiology Reviews · doi:10.1128/cmr.11.2.382 · Cited by 1,353
Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences
Sanglard, D., & Odds, F. C. (2002) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(02)00181-0 · Cited by 784
Self-citationMechanisms of Antifungal Drug Resistance
Cowen, L. E., Sanglard, D., Howard, S. J., Rogers, P. D., & Perlin, D. S. (2015) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a019752 · Cited by 647
Self-citationThe Evolution of Fungicide Resistance
Lucas, J. A., Hawkins, N. J., & Fraaije, B. A. (2015) · Advances in Applied Microbiology · doi:10.1016/bs.aambs.2014.09.001 · Cited by 638
Resistance to Antifungal Agents: Mechanisms and Clinical Impact
Kanafani, Z. A., & Perfect, J. R. (2008) · Clinical Infectious Diseases · doi:10.1086/524071 · Cited by 619
Metadata
- Authors
- Sanglard, D., Ischer, F., Koymans, L., & Bille, J.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 1998-02
- Volume
- 42
- Issue
- 2
- Pages
- 241-253
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2910992897
- Cited by
- 465
- References
- 42
- FWCI
- 15.35
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.